Drotrecogin alfa - Wikipedia, the free encyclopedia
Drotrecogin alfa (activated) (Xigris, marketed by Eli Lilly and Company) is a recombinant form of human activated protein C that has anti-thrombotic, ...
http://en.wikipedia.org/wiki/Drotrecogin_alfa...
|
Controversy Brews Over Xigris' Role in Treating Sepsis
1 Oct 2002 ... Some experts believe that the data are encouraging but insufficient for standard of care, while Lilly and the FDA justify their positions.
http://www.medscape.com/viewarticle/442255...
|
Eli Lilly and Company » Xigris® Media Kit
We are pleased to provide you with this resource on Xigris®. By providing you with this extensive online guide, our goal is to help you tell the story about
...
http://www.lilly.com/news/kits/xigris/...
|
Early Communication about an Ongoing Safety Review Xigris ...
5 Jan 2010 ... Early Communication about an Ongoing Safety Review Xigris (Drotrecogin alfa [ activated])
http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInfo...
|
Low-Dose, Off-Label Drotrecogin Alfa (Xigris) In Severe Sepsis
In this article, we describe a successful low-dose, off-label usage of drotrecogin alfa (Xigris), given at 18 mcg/kg per hour, in a patient with severe
...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2730102/...
|
Pediatric Xigris Study Stopped
29 Apr 2005 ... Interim results showed that drotrecogin alfa is unlikely to have any benefit over placebo.
http://www.medscape.com/viewarticle/504029...
|
Xigris [drotrecogin alfa (activated)] Discontinuation of Study
19 Jun 2009 ... Eli Lilly and FDA notified healthcare professionals of the stopping of enrollment in a randomized, double-blind, placebo-controlled trial of ...
http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyA...
|
Xigris May Increase Mortality in Lower-Risk Sepsis Patients
18 Mar 2005 ... Drotrecogin alfa injection was linked to increased mortality in recent postsurgical patients with single-organ dysfunction, according to the ...
http://www.medscape.com/viewarticle/501651...
|
Xigris (Drotrecogin alfa [activated]) - Early Communication about ...
4 Feb 2009 ... The finding by Gentry et al. of an increased risk of death and serious bleeding events in patients treated with Xigris who also have ...
http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyA...
|
FDA Continues to Investigate Bleeding Risk for Xigris
4 Feb 2009 ... The Food and Drug Administration announced today that is continuing to evaluate the incidence of serious bleeding events and death in ...
http://www.medscape.com/viewarticle/587847...
|
